Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cocktail aims to outsmart resistant myeloma

NCT ID NCT05675449

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The main goal is to check safety and find the right doses. About 59 participants will be treated for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Elranatamab (a drug that helps the immune system attack cancer cells) combined with either carfilzomib plus dexamethasone or maplirpacept
What this could lead to
If successful, this could point toward new combination treatments for multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) study with only 59 people, focused on safety and dosing—not yet on effectiveness. The combinations may cause side effects or fail to work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

59 people

The number who actually took part.

Started

Dec 2022

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prior diagnosis of multiple myeloma as defined by IMWG criteria. * Measurable disease based on IMWG criteria as defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL. * Urinary M-protein excretion ≥200 mg/24 hours. * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65). * Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy). * Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody. * ECOG performance status 0-1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1. * Not pregnant or breastfeeding and willing to use contraception. Exclusion Criteria: * Plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM * Impaired cardiovascular function or clinically significant cardiovascular diseases. * Participants with any active, uncontrolled bacterial, fungal, or viral infection. * Stem cell transplant within 12 weeks prior to enrollment, or active graft versus host disease. * Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * Part 1: Previous treatment with a BCMA-directed therapy. * Part 2: Previous treatment with any anti-BCMA directed therapy, with the exception of CAR-T. Previous treatment with a CD47-SIRP alpha-directed therapy. * Part 1: Prior treatment with carfilzomib * Live attenuated vaccine within 4 weeks of the first dose of study intervention. * Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study. * Any of the following within 3 months of enrollment: erosive esophagitis, treatment resistant peptic ulcer, infectious or inflammatory bowel disease, pulmonary embolism or uncontrolled thromboembolic event. * Intolerance to or participants who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or therapeutic proteins

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211, United States

  • Clinical Research Advisors (Encino Satellite Location)

    Encino, California, 91316, United States

  • Clinical Research Advisors (Korea Town Satellite Location)

    Los Angeles, California, 90020, United States

  • Clinical Research Advisors (West Hollywood Satellite Location)

    Los Angeles, California, 90048, United States

  • Dana Farber/Mass General Brigham Cancer Care, Inc

    Boston, Massachusetts, 02115, United States

  • Division of Hematology Hadassah Medical Center - Ein Kerem

    Jerusalem, 9112001, Israel

  • Emory University Administration Office

    Atlanta, Georgia, 30322, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Griffin Cancer Research Building (GCRB)

    Miami, Florida, 33136, United States

  • Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital

    Petah Tikva, 4941492, Israel

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee, 37232, United States

  • Johns Hopkins University Cancer Immunology/GI Oncology

    Baltimore, Maryland, 21287, United States

  • MSK Monmouth

    Middletown, New Jersey, 07748, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York, 10021, United States

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York, 10065, United States

  • Oncology Investigational Drug Service,Department of Pharmacy Services

    Baltimore, Maryland, 21231, United States

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus

    Haifa, 3109601, Israel

  • State University of Iowa, Division of Sponsored Programs

    Iowa City, Iowa, 52242, United States

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • Sylvester Comprehensive Cancer Center - Aventura

    Aventura, Florida, 33180, United States

  • Sylvester Comprehensive Cancer Center - Coral Springs

    Coral Springs, Florida, 33065, United States

  • Sylvester Comprehensive Cancer Center - Hollywood

    Hollywood, Florida, 33021, United States

  • Sylvester Comprehensive Cancer Center - Kendall

    Miami, Florida, 33176, United States

  • Sylvester Comprehensive Cancer Center - Plantation

    Plantation, Florida, 33324, United States

  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center

    Coral Gables, Florida, 33146, United States

  • The Research Fund of Hadassah Medical Organization (R.A.)

    Jerusalem, 9112001, Israel

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231, United States

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242, United States

  • University of Miami Hospital and Clinics

    Miami, Florida, 33136, United States

  • University of Miami Hospital and Clinics - Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.